{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T05:43:28Z","timestamp":1783230208126,"version":"3.54.6"},"reference-count":152,"publisher":"Elsevier","isbn-type":[{"value":"9780443193460","type":"print"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004728","name":"VIT University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004728","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.apcsb.2023.12.017","type":"book-chapter","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T12:50:39Z","timestamp":1717591839000},"page":"293-328","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic potentials of glucose-dependent insulinotropic polypeptide (GIP) in T2DM: Past, present, and future"],"prefix":"10.1016","author":[{"given":"Soumik","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harini","family":"Ravi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achsha","family":"Babu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manosi","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kanagavalli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivaraman","family":"Dhanasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Devi Rajeswari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Venkatraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gnanasambandan","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.017_bib1","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.2337\/db12-0976","article-title":"Link between GIP and osteopontin in adipose tissue and insulin resistance","volume":"62","author":"Ahlqvist","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib2","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2147\/DMSO.S387116","article-title":"The efficacy of GLP-1 analogues on appetite parameters, gastric emptying, food preference and taste among adults with obesity: Systematic review of randomized controlled trials","volume":"16","author":"Aldawsari","year":"2023","journal-title":"Diabetes, Metabolic Syndrome and Obesity"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jama.298.2.194","article-title":"Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis","volume":"298","author":"Amori","year":"2007","journal-title":"JAMA: The Journal of the American Medical Association"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib4","doi-asserted-by":"crossref","unstructured":"Associazione Italiana per lo Studio del Fegato (AISF), Societ\u00e0 Italiana di Diabetologia (SID) and Societ\u00e0 Italiana dell\u2019Obesit\u00e0 (SIO) Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO) (2022). Digestive and Liver Disease 54(2), 170-182. https:\/\/doi.org\/10.1016\/j.dld.2021.04.029.","DOI":"10.1016\/j.dld.2021.04.029"},{"issue":"16","key":"10.1016\/bs.apcsb.2023.12.017_bib5","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1080\/14656566.2021.1939676","article-title":"Ertugliflozin+ metformin as a treatment option for type 2 diabetes","volume":"22","author":"Athyros","year":"2021","journal-title":"Expert Opinion on Pharmacotherapy"},{"issue":"Pt 2","key":"10.1016\/bs.apcsb.2023.12.017_bib6","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/brain\/aws009","article-title":"Parkinson\u2019s disease, insulin resistance and novel agents of neuroprotection","volume":"136","author":"Aviles-Olmos","year":"2013","journal-title":"Brain"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-018-0315-6","article-title":"Treatment with PBI-4050 in patients with Alstr\u00f6m syndrome: Study protocol for a phase 2, single-Centre, single-arm, open-label trial","volume":"18","author":"Baig","year":"2018","journal-title":"BMC Endocrine Disorders"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.017_bib8","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1515\/bchm3.1992.373.2.353","article-title":"Oligopeptidases, and the emergence of the prolyl oligopeptidase family","volume":"373","author":"Barrett","year":"1992","journal-title":"Biological Chemistry Hoppe-Seyler"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.017_bib9","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1007\/s13300-023-01451-z","article-title":"Patient-reported outcomes in people with type 2 diabetes receiving tirzepatide in the SURPASS clinical trial programme","volume":"14","author":"Boye","year":"2023","journal-title":"Diabetes Therapy"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.017_bib10","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.2337\/dc19-0167","article-title":"Role of vitamin E for nonalcoholic steatohepatitis in patients with type 2 diabetes: A randomized controlled trial","volume":"42","author":"Bril","year":"2019","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.017_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11892-020-01349-1","article-title":"Role of agents for the treatment of diabetes in the management of nonalcoholic fatty liver disease","volume":"20","author":"Budd","year":"2020","journal-title":"Current Diabetes Reports"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.017_bib12","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1210\/endo.137.7.8770921","article-title":"Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor","volume":"137","author":"Bullock","year":"1996","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.017_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metabolism"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.017_bib14","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1210\/endo.134.5.8156917","article-title":"Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse","volume":"134","author":"Campos","year":"1994","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.017_bib15","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1210\/er.2018-00117","article-title":"Targeting the incretin\/glucagon system with triagonists to treat diabetes","volume":"39","author":"Capozzi","year":"2018","journal-title":"Endocrine Reviews"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.017_bib16","doi-asserted-by":"crossref","first-page":"E908","DOI":"10.1210\/jc.2013-3350","article-title":"Disruption of GIP\/GIPR axis in human adipose tissue is linked to obesity and insulin resistance","volume":"99","author":"Ceperuelo-Mallafre","year":"2014","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.017_bib17","doi-asserted-by":"crossref","first-page":"E414","DOI":"10.1152\/ajpendo.00418.2014","article-title":"Increased GIP signaling induces adipose inflammation via a HIF-1\u03b1-dependent pathway and impairs insulin sensitivity in mice","volume":"308","author":"Chen","year":"2015","journal-title":"American Journal of Physiology-Endocrinology and Metabolism"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.017_bib18","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2337\/db08-0958","article-title":"Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes","volume":"58","author":"Chia","year":"2009","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.regpep.2004.08.004","article-title":"The [pre-] history of the incretin concept","volume":"128","author":"Creutzfeldt","year":"2005","journal-title":"Regulatory Peptides"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/BF00429703","article-title":"Gastric inhibitory polypeptide (GIP) and insulin in obesity: Increased response to stimulation and defective feedback control of serum levels","volume":"14","author":"Creutzfeldt","year":"1978","journal-title":"Diabetologia"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.017_bib21","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S2468-1253(21)00300-9","article-title":"Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): A randomised, double-blind, placebo-controlled, phase 2a study","volume":"6","author":"Cusi","year":"2021","journal-title":"The Lancet Gastroenterology and Hepatology"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.017_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050117","article-title":"Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists","volume":"7","author":"Cuthbertson","year":"2012","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib23","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S0149-2918(03)80090-5","article-title":"Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: A one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors","volume":"25","author":"Derosa","year":"2003","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.017_bib24","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1016\/j.peptides.2006.05.011","article-title":"Effects of glucose-dependent insulinotropic peptide on behavior","volume":"27","author":"Ding","year":"2006","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib25","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI5001","article-title":"Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity","volume":"103","author":"Dresner","year":"1999","journal-title":"The Journal of Clinical Investigation"},{"issue":"10","key":"10.1016\/bs.apcsb.2023.12.017_bib26","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1073\/pnas.84.10.3434","article-title":"Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line","volume":"84","author":"Drucker","year":"1987","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.017_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.bcp.2011.11.028","article-title":"DPP-4 inhibitors in the treatment of type 2 diabetes","volume":"83","author":"Duez","year":"2012","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.neuroscience.2012.10.045","article-title":"The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP\/PS1 mouse model of Alzheimer\u2019s disease","volume":"228","author":"Duffy","year":"2013","journal-title":"Neuroscience"},{"issue":"15","key":"10.1016\/bs.apcsb.2023.12.017_bib29","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.3390\/ijms20153711","article-title":"Oxidative stress in the pathogenesis and evolution of chronic kidney disease: Untangling Ariadne\u2019s thread","volume":"20","author":"Duni","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.017_bib30","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/jcem-37-5-826","article-title":"Stimulation of insulin secretion by gastric inhibitory polypeptide in man","volume":"37","author":"Dupre","year":"1973","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib31","unstructured":"Dysted, M. P., Eszterg\u00e1lyos, B., Gautam, S., Helman, B., Pinkepank, M., Randi, A., et al. (2021). IDF diabetes atlas (10th ed.). International Diabetes Federation."},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02581191","article-title":"Gastric inhibitory polypeptide (GIP) hypersecretion in obesity depends on meal size and is not related to hyperinsulinemia","volume":"26","author":"Ebert","year":"1989","journal-title":"Acta Diabetologica Latina"},{"issue":"10","key":"10.1016\/bs.apcsb.2023.12.017_bib33","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1210\/en.2002-0068","article-title":"Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase","volume":"144","author":"Ehses","year":"2003","journal-title":"Endocrinology"},{"issue":"26","key":"10.1016\/bs.apcsb.2023.12.017_bib34","doi-asserted-by":"crossref","first-page":"23667","DOI":"10.1074\/jbc.M103023200","article-title":"A new pathway for glucose-dependent insulinotropic polypeptide (GIP) receptor signaling: Evidence for the involvement of phospholipase A2 in GIP-stimulated insulin secretion","volume":"276","author":"Ehses","year":"2001","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170213","article-title":"The role of GIP in alpha-cells and glucagon secretion","volume":"125","author":"El","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib36","doi-asserted-by":"crossref","first-page":"170213","DOI":"10.1016\/j.peptides.2019.170213","article-title":"The role of GIP in alpha-cells and glucagon secretion","volume":"125","author":"El","year":"2020","journal-title":"Peptides"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.017_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1948","article-title":"GIP mediates the incretin effect and glucose tolerance by dual actions on alpha cells and beta cells","volume":"7","author":"El","year":"2021","journal-title":"Science Advances"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib38","unstructured":"Eli Lilly, C. (2019). A study of tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with type 2 diabetes (SURPASS-CVOT). ClinicalTrial.gov."},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.017_bib39","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.2337\/db16-0240","article-title":"Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation","volume":"65","author":"Faerch","year":"2016","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib40","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/alzrt174","article-title":"Neuroprotective effects of D-Ala(2)GIP on Alzheimer\u2019s disease biomarkers in an APP\/PS1 mouse model","volume":"5","author":"Faivre","year":"2013","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.017_bib41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nrcardio.2017.224","article-title":"Nitric oxide signalling in cardiovascular health and disease","volume":"15","author":"Farah","year":"2018","journal-title":"Nature Reviews Cardiology"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.017_bib42","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1210\/edrv-16-3-390","article-title":"Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide","volume":"16","author":"Fehmann","year":"1995","journal-title":"Endocrine Reviews"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.017_bib43","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson","year":"2021","journal-title":"Nature Reviews Endocrinology"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.017_bib44","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ki.2013.427","article-title":"The protective roles of GLP-1R signaling in diabetic nephropathy: Possible mechanism and therapeutic potential","volume":"85","author":"Fujita","year":"2014","journal-title":"Kidney International"},{"issue":"22","key":"10.1016\/bs.apcsb.2023.12.017_bib45","doi-asserted-by":"crossref","first-page":"13546","DOI":"10.1021\/acs.jmedchem.0c00944","article-title":"Discovery of PF-06835919: A potent inhibitor of ketohexokinase (KHK) for the treatment of metabolic disorders driven by the overconsumption of fructose","volume":"63","author":"Futatsugi","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib46","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/107632701300003278","article-title":"The effect of zinc-crystallized glucagon-like peptide-1 on insulin secretion of macroencapsulated pancreatic islets","volume":"7","author":"Gappa","year":"2001","journal-title":"Tissue Engineering"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib47","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4158\/EP161682.CS","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm\u20142017 executive summary","volume":"23","author":"Garber","year":"2017","journal-title":"Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.017_bib48","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1574886313666180601082412","article-title":"Risk and benefit profile of dulaglutide in established therapeutic indication","volume":"13","author":"Garg","year":"2018","journal-title":"Current Drug Safety"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib49","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s40265-017-0697-1","article-title":"Saxagliptin\/Dapagliflozin: A review in type 2 diabetes mellitus","volume":"77","author":"Garnock-Jones","year":"2017","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib50","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0006-291X(03)01361-5","article-title":"Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes","volume":"308","author":"Gault","year":"2003","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.017_bib51","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.bcp.2008.03.011","article-title":"C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes","volume":"75","author":"Gault","year":"2008","journal-title":"Biochemical Pharmacology"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib52","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1677\/joe.0.1750525","article-title":"Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo","volume":"175","author":"Gault","year":"2002","journal-title":"The Journal of Endocrinology"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib53","first-page":"60","article-title":"GIP-based therapeutics for diabetes and obesity","volume":"2","author":"Gault","year":"2008","journal-title":"Current Chemical Biology"},{"issue":"10193","key":"10.1016\/bs.apcsb.2023.12.017_bib54","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib55","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.diabres.2019.03.024","article-title":"Treatment of type 2 diabetes mellitus worldwide: Baseline patient characteristics in the global DISCOVER study","volume":"151","author":"Gomes","year":"2019","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib56","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1515\/BC.2004.035","article-title":"Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues","volume":"385","author":"Green","year":"2004","journal-title":"Biological Chemistry"},{"issue":"29","key":"10.1016\/bs.apcsb.2023.12.017_bib57","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.2174\/1381612043382774","article-title":"Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents","volume":"10","author":"Green","year":"2004","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib58","unstructured":"Gupta, K., & Raja, A. (2023). Physiology, gastric inhibitory peptide. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Avais Raja declares no relevant financial relationships with ineligible companies."},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.017_bib59","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2337\/diacare.19.8.843","article-title":"Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet","volume":"19","author":"Gutniak","year":"1996","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.017_bib60","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.jhep.2019.10.023","article-title":"Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study","volume":"72","author":"Harrison","year":"2020","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.017_bib61","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: Post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.017_bib62","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1","volume":"87","author":"Holst","year":"2007","journal-title":"Physiological Reviews"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0014-5793(87)81430-8","article-title":"Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut","volume":"211","author":"Holst","year":"1987","journal-title":"FEBS Letters"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib64","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2337\/diabetes.53.1.5","article-title":"Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell","volume":"53","author":"Holz","year":"2004","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.017_bib65","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1210\/mend-3-6-1014","article-title":"Gastric inhibitory polypeptide: Structure and chromosomal localization of the human gene","volume":"3","author":"Inagaki","year":"1989","journal-title":"Molecular Endocrinology (Baltimore, Md.)"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib66","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s42000-018-0021-9","article-title":"The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD)","volume":"17","author":"Iogna Prat","year":"2018","journal-title":"Hormones (Athens)"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.017_bib67","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.bcp.2006.06.013","article-title":"Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide","volume":"72","author":"Irwin","year":"2006","journal-title":"Biochemical Pharmacology"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.017_bib68","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1021\/jm049262s","article-title":"Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide","volume":"48","author":"Irwin","year":"2005","journal-title":"Journal of Medicinal Chemistry"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.017_bib69","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1124\/jpet.105.086082","article-title":"A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes","volume":"314","author":"Irwin","year":"2005","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib70","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/jnc.13736","article-title":"Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH-SY5Y cells","volume":"139","author":"Jalewa","year":"2016","journal-title":"Journal of Neurochemistry"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib71","doi-asserted-by":"crossref","first-page":"474","DOI":"10.2337\/diabetes.53.2.474","article-title":"Increased risk of type 2 diabetes in Alzheimer disease","volume":"53","author":"Janson","year":"2004","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.017_bib72","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: A narrative review","volume":"39","author":"Jensterle","year":"2022","journal-title":"Advances in Therapy"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.017_bib73","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1080\/1061186X.2019.1566342","article-title":"ANGPTL3: A novel biomarker and promising therapeutic target","volume":"27","author":"Jiang","year":"2019","journal-title":"Journal of Drug Targeting"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.017_bib74","doi-asserted-by":"crossref","first-page":"868","DOI":"10.2337\/db16-0758","article-title":"Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet-fed mice","volume":"66","author":"Joo","year":"2017","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib75","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"European Journal of Heart Failure: Journal of the Working Group on Heart Failure of the European Society of Cardiology"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib76","first-page":"615","article-title":"TRC150094, a novel mitochondrial modulator, reduces cardio-metabolic risk as an add-on treatment: A phase-2, 24-week, multi-center, randomized, double-blind, clinical trial","volume":"25","author":"Joshi","year":"2022","journal-title":"Diabetes, Metabolic Syndrome and Obesity"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib77","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12933-022-01454-3","article-title":"The gut hormone glucose-dependent insulinotropic polypeptide is downregulated in response to myocardial injury","volume":"21","author":"Kahles","year":"2022","journal-title":"Cardiovascular Diabetology"},{"issue":"47","key":"10.1016\/bs.apcsb.2023.12.017_bib78","doi-asserted-by":"crossref","first-page":"34139","DOI":"10.1074\/jbc.M704896200","article-title":"Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes","volume":"282","author":"Kim","year":"2007","journal-title":"The Journal of Biological Chemistry"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.017_bib79","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1128\/MCB.00325-07","article-title":"Glucose-dependent insulinotropic polypeptide-mediated up-regulation of beta-cell antiapoptotic Bcl-2 gene expression is coordinated by cyclic AMP (cAMP) response element binding protein (CREB) and cAMP-responsive CREB coactivator 2","volume":"28","author":"Kim","year":"2008","journal-title":"Molecular and Cellular Biology"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.017_bib80","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.2337\/db07-0100","article-title":"Reduced incretin effect in type 2 diabetes: Cause or consequence of the diabetic state?","volume":"56","author":"Knop","year":"2007","journal-title":"Diabetes"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib81","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"issue":"2-3","key":"10.1016\/bs.apcsb.2023.12.017_bib82","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0014-2999(96)00795-9","article-title":"Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor","volume":"318","author":"Knudsen","year":"1996","journal-title":"European Journal of Pharmacology"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.017_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103981","article-title":"Preclinical characterization of recombinant human tissue kallikrein-1 as a novel treatment for type 2 diabetes mellitus","volume":"9","author":"Kolodka","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib84","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/oby.23612","article-title":"Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program","volume":"31","author":"Le Roux","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"10","key":"10.1016\/bs.apcsb.2023.12.017_bib85","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1210\/endo.141.10.7750","article-title":"Glucose-dependent insulinotropic polypeptide confers early phase insulin release to oral glucose in rats: Demonstration by a receptor antagonist","volume":"141","author":"Lewis","year":"2000","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.017_bib86","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1210\/me.2002-0084","article-title":"Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism","volume":"16","author":"Light","year":"2002","journal-title":"Molecular Endocrinology (Baltimore, Md.)"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.017_bib87","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/00325481.2020.1750228","article-title":"Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes","volume":"132","author":"Lingvay","year":"2020","journal-title":"Postgraduate Medicine"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.017_bib88","first-page":"829","article-title":"Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: A multicentre, double-blind, randomised, placebo-controlled phase 2 trial","volume":"5","author":"Loomba","year":"2020"},{"issue":"2-3","key":"10.1016\/bs.apcsb.2023.12.017_bib89","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.regpep.2010.04.009","article-title":"The direct effects of GLP-1 and GIP, alone or in combination, on human pancreatic islets","volume":"165","author":"Lupi","year":"2010","journal-title":"Regulatory Peptides"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.017_bib90","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.3390\/ijms15045596","article-title":"Transcriptional analysis of apoptotic cerebellar granule neurons following rescue by gastric inhibitory polypeptide","volume":"15","author":"Maino","year":"2014","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib91","doi-asserted-by":"crossref","DOI":"10.7573\/dic.2020-7-4","article-title":"Ertugliflozin in the treatment of type 2 diabetes mellitus","volume":"9","author":"Marrs","year":"2020","journal-title":"Drugs in Context"},{"issue":"19","key":"10.1016\/bs.apcsb.2023.12.017_bib92","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.017_bib93","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.017_bib94","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.amjcard.2018.02.030","article-title":"Myocardial infarction subtypes in patients with type 2 diabetes mellitus and the effect of liraglutide therapy (from the LEADER trial)","volume":"121","author":"Marso","year":"2018","journal-title":"The American Journal of Cardiology"},{"issue":"17","key":"10.1016\/bs.apcsb.2023.12.017_bib95","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.3390\/ijms20174092","article-title":"The effects of dual GLP-1\/GIP receptor agonism on glucagon secretion\u2014A review","volume":"20","author":"Mathiesen","year":"2019","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.748157","article-title":"Prevalence, awareness, treatment and control of diabetes in India from the countrywide national NCD monitoring survey","volume":"10","author":"Mathur","year":"2022","journal-title":"Frontiers in Public Health"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib97","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0083-6729(08)00615-8","article-title":"Glucose-dependent insulinotropic polypeptide (Gastric Inhibitory Polypeptide; GIP)","volume":"80","author":"McIntosh","year":"2009","journal-title":"Vitamins and Hormones"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib98","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.2040-1124.2012.00196.x","article-title":"Glucose-dependent insulinotropic polypeptide signaling in pancreatic beta-cells and adipocytes","volume":"3","author":"McIntosh","year":"2012","journal-title":"Journal of Diabetes Investigation"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.017_bib99","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/diabetes.53.3.654","article-title":"Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.017_bib100","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1177\/8755122518790925","article-title":"Semaglutide for the treatment of type 2 diabetes mellitus","volume":"34","author":"Miles","year":"2018","journal-title":"Journal of Pharmacy Technology"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib101","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Therapy"},{"issue":"4","key":"10.1016\/bs.apcsb.2023.12.017_bib102","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041509","article-title":"GIP as a potential therapeutic target for atherosclerotic cardiovascular disease\u2014A systematic review","volume":"21","author":"Mori","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib103","doi-asserted-by":"crossref","DOI":"10.1177\/10742484221146371","volume":"27","author":"Muzurovic","year":"2022","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib104","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/DMSO.S297353","article-title":"GIP receptor antagonist, SKL-14959 indicated alteration of the lipids metabolism to catabolism by the inhibition of plasma LPL activity, resulting in the suppression of weight gain on diets-induced obesity mice","volume":"14","author":"Nakamura","year":"2021","journal-title":"Diabetes, Metabolic Syndrome and Obesity"},{"issue":"3","key":"10.1016\/bs.apcsb.2023.12.017_bib105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/dom.12591","article-title":"Incretin therapies: Highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors","volume":"18","author":"Nauck","year":"2016","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib107","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib108","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib109","doi-asserted-by":"crossref","first-page":"6666","DOI":"10.1038\/s41598-022-10577-2","article-title":"Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis","volume":"12","author":"Nestor","year":"2022","journal-title":"Scientific Reports"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.017_bib110","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00125-002-0894-6","article-title":"Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP","volume":"45","author":"O\u2019Harte","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib111","article-title":"Characterisation of glucose-dependent insulinotropic polypeptide receptor antagonists in rodent pancreatic beta cells and mice","volume":"12","author":"Perry","year":"2019","journal-title":"Clinical Medicine Insights: Endocrinology and Diabetes"},{"issue":"2-3","key":"10.1016\/bs.apcsb.2023.12.017_bib112","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejphar.2010.10.059","article-title":"Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice","volume":"650","author":"Porter","year":"2011","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib113","unstructured":"Release, F. N. (2022). FDA Approves novel, dual-targeted treatment for type 2 diabetes: FDA Retrieved from https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-novel-dual-targeted-treatment-type-2-diabetes."},{"key":"10.1016\/bs.apcsb.2023.12.017_bib114","series-title":"The epidemiology of diabetic kidney disease","first-page":"499","author":"Reutens","year":"2008"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.017_bib115","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1021\/acs.jmedchem.5b01198","article-title":"G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: Recent progress and prevailing challenges","volume":"59","author":"Ritter","year":"2016","journal-title":"Journal of Medicinal Chemistry"},{"issue":"7785","key":"10.1016\/bs.apcsb.2023.12.017_bib116","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib117","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1038\/s41598-018-21056-y","article-title":"Crystal structures of a bacterial dipeptidyl peptidase IV reveal a novel substrate recognition mechanism distinct from that of mammalian orthologues","volume":"8","author":"Roppongi","year":"2018","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib118","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/2589977513666210211163711","article-title":"Drug repurposing: An emerging tool for drug reuse, recycling and discovery","volume":"13","author":"Roy","year":"2021","journal-title":"Current Drug Research Reviews"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.017_bib119","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends in Endocrinology and Metabolism: TEM"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib120","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1124\/jpet.112.192096","article-title":"MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo","volume":"342","author":"Saporito","year":"2012","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.017_bib121","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/17425255.2016.1215427","article-title":"DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: From rationale to clinical aspects","volume":"12","author":"Scheen","year":"2016","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"issue":"1-2","key":"10.1016\/bs.apcsb.2023.12.017_bib122","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.2040-1124.2010.00022.x","article-title":"GIP and GLP-1, the two incretin hormones: Similarities and differences","volume":"1","author":"Seino","year":"2010","journal-title":"Journal of Diabetes Investigation"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib123","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdi.12065","article-title":"Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas","volume":"4","author":"Seino","year":"2013","journal-title":"Journal of Diabetes Investigation"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.017_bib124","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/jdi.13816","article-title":"Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity","volume":"13","author":"Seino","year":"2022","journal-title":"Journal of Diabetes Investigation"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.017_bib125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025269","article-title":"GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy","volume":"6","author":"Sharma","year":"2011","journal-title":"PLoS One"},{"issue":"49","key":"10.1016\/bs.apcsb.2023.12.017_bib126","doi-asserted-by":"crossref","first-page":"19333","DOI":"10.1073\/pnas.0707054104","article-title":"Essential role of Epac2\/Rap1 signaling in regulation of insulin granule dynamics by cAMP","volume":"104","author":"Shibasaki","year":"2007","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib127","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7570\/jomes22067","article-title":"Efficacy and safety of tirzepatide in type 2 diabetes and obesity management","volume":"32","author":"Sinha","year":"2023","journal-title":"Journal of Obesity & Metabolic Syndrome"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.017_bib128","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1111\/j.1478-3231.2011.02462.x","article-title":"Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis","volume":"31","author":"Svegliati-Baroni","year":"2011","journal-title":"Liver International: Official Journal of the International Association for the Study of the Liver"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib129","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib130","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170208","article-title":"The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)","volume":"125","author":"Thondam","year":"2020","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib131","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1152\/ajpendo.00100.2012","article-title":"Glucose-dependent insulinotropic polypeptide induces cytokine expression, lipolysis, and insulin resistance in human adipocytes","volume":"304","author":"Timper","year":"2013","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"9","key":"10.1016\/bs.apcsb.2023.12.017_bib132","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1369\/jhc.2008.951319","article-title":"Expression of the GLP-1 receptor in mouse, rat, and human pancreas","volume":"56","author":"Tornehave","year":"2008","journal-title":"The Journal of Histochemistry and Cytochemistry: Official Journal of the Histochemistry Society"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.017_bib133","article-title":"Role of Ertugliflozin in the management of diabetes mellitus","volume":"14","author":"Totade","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib134","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40265-020-01278-z","article-title":"Glucokinase activators for type 2 diabetes: Challenges and future developments","volume":"80","author":"Toulis","year":"2020","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/bs.apcsb.2023.12.017_bib135","first-page":"G762","article-title":"Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice","volume":"302","author":"Trevaskis","year":"2012","journal-title":"American Journal of"},{"issue":"2","key":"10.1016\/bs.apcsb.2023.12.017_bib136","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1677\/joe.0.1740233","article-title":"Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells","volume":"174","author":"Trumper","year":"2002","journal-title":"The Journal of Endocrinology"},{"issue":"Pt 2","key":"10.1016\/bs.apcsb.2023.12.017_bib137","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1042\/bj20021288","article-title":"Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells","volume":"369","author":"Tsuboi","year":"2003","journal-title":"The Biochemical Journal"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib138","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jdiacomp.2016.10.007","article-title":"Role of continuous glucose monitoring for type 2 in diabetes management and research","volume":"31","author":"Vigersky","year":"2017","journal-title":"Journal of Diabetes and its Complications"},{"issue":"6","key":"10.1016\/bs.apcsb.2023.12.017_bib139","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/dom.13981","article-title":"Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add\u2010on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel\u2010design, open\u2010label, Phase 3 trial","volume":"22","author":"Vilsb\u00f8ll","year":"2020","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"11","key":"10.1016\/bs.apcsb.2023.12.017_bib140","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/ijo.2008.148","article-title":"Functional expression of glucose-dependent insulinotropic polypeptide receptors is coupled to differentiation in a human adipocyte model","volume":"32","author":"Weaver","year":"2008","journal-title":"International Journal of Obesity (London)"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.017_bib141","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/dom.14009","article-title":"The methionine aminopeptidase 2 inhibitor ZGN\u20101061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo\u2010controlled trial","volume":"22","author":"Wentworth","year":"2020","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"44","key":"10.1016\/bs.apcsb.2023.12.017_bib142","doi-asserted-by":"crossref","first-page":"30372","DOI":"10.1074\/jbc.M109.060178","article-title":"Suppression of p38 MAPK and JNK via Akt-mediated inhibition of apoptosis signal-regulating kinase 1 constitutes a core component of the beta-cell pro-survival effects of glucose-dependent insulinotropic polypeptide","volume":"284","author":"Widenmaier","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"issue":"16","key":"10.1016\/bs.apcsb.2023.12.017_bib143","doi-asserted-by":"crossref","first-page":"10764","DOI":"10.1074\/jbc.M809116200","article-title":"Noncanonical activation of Akt\/protein kinase B in beta-cells by the incretin hormone glucose-dependent insulinotropic polypeptide","volume":"284","author":"Widenmaier","year":"2009","journal-title":"The Journal of Biological Chemistry"},{"issue":"17","key":"10.1016\/bs.apcsb.2023.12.017_bib144","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.017_bib145","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1111\/dom.14174","article-title":"The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes","volume":"22","author":"Wilson","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"7","key":"10.1016\/bs.apcsb.2023.12.017_bib146","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.21037\/jtd.2017.06.70","article-title":"Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus","volume":"9","author":"Yandrapalli","year":"2017","journal-title":"Journal of Thoracic Disease"},{"issue":"12","key":"10.1016\/bs.apcsb.2023.12.017_bib147","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.7150\/thno.15993","article-title":"Activation of GLP-1 receptor enhances neuronal base excision repair via PI3K-AKT-induced expression of apurinic\/apyrimidinic endonuclease 1","volume":"6","author":"Yang","year":"2016","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/bs.apcsb.2023.12.017_bib148","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.bbrc.2017.11.076","article-title":"Recombinant human GLP-1 (rhGLP-1) alleviating renal tubulointestitial injury in diabetic STZ-induced rats","volume":"495","author":"Yin","year":"2018","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"9309","key":"10.1016\/bs.apcsb.2023.12.017_bib149","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.017_bib150","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/liv.12120","article-title":"GLP-1 analogue prevents NAFLD in ApoE KO mice with diet and Acrp30 knockdown by inhibiting c-JNK","volume":"33","author":"Zhang","year":"2013","journal-title":"Liver International: Official Journal of the International Association for the Study of the Liver"},{"key":"10.1016\/bs.apcsb.2023.12.017_bib151","article-title":"Efficacy and safety of dulaglutide in patients with type 2 diabetes: A meta-analysis and systematic review","volume":"6","author":"Zhang","year":"2016","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1016\/bs.apcsb.2023.12.017_bib152","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41591-022-01802-6","article-title":"Dorzagliatin in drug-na\u00efve patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"28","author":"Zhu","year":"2022","journal-title":"Nature Medicine"}],"container-title":["Advances in Protein Chemistry and Structural Biology","Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162323001293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876162323001293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T06:08:38Z","timestamp":1721887718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876162323001293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443193460"],"references-count":152,"URL":"https:\/\/doi.org\/10.1016\/bs.apcsb.2023.12.017","relation":{},"ISSN":["1876-1623"],"issn-type":[{"value":"1876-1623","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}